Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | TDO2 | P48775 | 2/20 | 0.43 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975957 | 0.85 | IDO1 (0.52) | TSHRLMNACYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL7520144 | 0.85 | IDO1 (0.52) | TSHRLMNACYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL9677445 | 0.83 | TSHR (0.47) | TSHRLMNACYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL11488224 | 0.82 | TSHR (0.58) | TSHRLMNACYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL4167758 | 0.81 | TSHR (0.47) | TSHRLMNACYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL13145151 | 0.79 | P2RX7 (0.47) | TSHRLMNACYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL5627145 | 0.79 | TSHR (0.43) | TSHRLMNACYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL320794 | 0.79 | P2RX7 (0.47) | TSHRLMNACYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL9503376 | 0.79 | ADRB2 (0.46) | TSHRLMNACYP2C19ALDH1A1CYP2C9 | |
| SCHEMBL11640013 | 0.79 | TSHR (0.42) | TSHRLMNACYP2C19ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910603-B2 | 3-monosubstituted tropane derivatives as nociceptin receptor ligands | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910603-B2 | 3-monosubstituted tropane derivatives as nociceptin receptor ligands | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090105248-A1 | 3-MONOSUBSTITUTED TROPANE DERIVATIVES AS NOCICEPTIN RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105248-A1 | 3-MONOSUBSTITUTED TROPANE DERIVATIVES AS NOCICEPTIN RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-7485650-B2 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485650-B2 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7479494-B2 | 3-monosubstituted tropane derivatives as nociceptin receptor ligands | SCHERING CORPORATION (US) | 2009-01-20 | — | — | US | disclosed |
| US-7479494-B2 | 3-monosubstituted tropane derivatives as nociceptin receptor ligands | SCHERING CORPORATION (US) | 2009-01-20 | — | — | US | disclosed |
| US-7459556-B2 | Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols | SCHERING-PLOUGH LTD. (CH) | 2008-12-02 | — | — | US | disclosed |
| US-20070249604-A1 | 3-Monosubstituted tropane derivatives as nociceptin receptor ligands | SCHERING CORPORATION | 2007-10-25 | — | — | US | disclosed |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| WO-2003039469-A2 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-0912176-B1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-25 | — | — | EP | disclosed |
| US-6451816-B1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH (DE) | 2002-09-17 | — | — | US | disclosed |
| EP-0934309-B1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-11 | — | — | EP | disclosed |
| US-6444823-B1 | ANTITUMOR AGENTS; IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | KLINGE PHARMA GMBH (DE) | 2002-09-03 | — | — | US | disclosed |
| EP-0934309-A1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | Klinge Pharma GmbH (DE) | 1999-08-11 | — | — | EP | disclosed |
| EP-0912176-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | Klinge Pharma GmbH (DE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048397-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048695-A1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105248-A1 | 3-MONOSUBSTITUTED TROPANE DERIVATIVES AS NOCICEPTIN RECEPTOR LIGANDS | OPRL1, OPRM1, OPRD1 | TSHR 230/4885LMNA 1291/4885CYP2C19 1783/4885 |
| US-20070249604-A1 | 3-Monosubstituted tropane derivatives as nociceptin receptor ligands | OPRL1, OPRM1, OPRD1 | TSHR 235/4885LMNA 1382/4885CYP2C19 1767/4885 |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | OPRL1, OPRD1, OPRK1 | TSHR 711/4885LMNA 2771/4885CYP2C19 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.